Marin-Acevedo, Julian A.Withycombe, Bethany M.Kim, YoungchulBrohl, Andrew S.Eroglu, ZeynepMarkowitz, JosephTarhini, Ahmad A.Tsai, Kenneth Y.Khushalani, Nikhil I.2024-01-182024-01-182023-06-14Marin-Acevedo JA, Withycombe BM, Kim Y, et al. Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma. Cancers (Basel). 2023;15(12):3180. Published 2023 Jun 14. doi:10.3390/cancers15123180https://hdl.handle.net/1805/38077Anti-PD1 therapy demonstrated impressive, prolonged responses in advanced cutaneous squamous cell carcinoma (CSCC). Therapy for ICI-refractory/ineligible disease remains unclear. We performed a retrospective analysis in locally-advanced/metastatic CSCC using cetuximab across three cohorts: immediately after ICI failure (A), not immediately following ICI failure (B), or without prior ICI (C). The primary endpoint was the overall response rate (ORR). Secondary endpoints included disease-control rate (DCR), progression-free survival (PFS), overall survival (OS), time-to-response (TTR) and toxicity. Twenty-three patients were included. In cohort A (n = 11), the ORR was 64% and DCR was 91%, with six ongoing responses at data cutoff. In cohort B (n = 2), all patients had progression as the best response. At a median follow-up of 21 months for A and B, TTR and PFS were 2.0 and 17.3 months, respectively. The median OS was not reached. In cohort C (n = 10), the ORR and DCR were 80%, including five ongoing responses at the data cutoff. At a median follow-up of 22.4 months, the TTR, PFS and OS were 2.5, 7.3 and 23.1 months, respectively. Cetuximab was well tolerated in all cohorts. In summary, cetuximab is effective in patients with failure/contraindications to ICI. Cetuximab immediately after ICI failure yielded particularly fast, durable responses. If confirmed, this could be the preferred therapy following ICI failure.en-USAttribution 4.0 InternationalCetuximabCutaneous squamous cell carcinomaImmune checkpoint inhibitorImmunodeficiencyImmunotherapyTherapeuticsArticle